comparemela.com

Latest Breaking News On - Bioinvent - Page 1 : comparemela.com

BioInvent International: BioInvent Announces Additional Efficacy Data from Intravenous Part of Phase 1/2 Trial with BI-1206 in Solid Tumors

One additional patient has developed a partial response (PR) and one patient has remained on stable disease for over 80 weeksThese long-lasting responses in hard-to-treat metastatic diseases, in patients

Mecklenburg vorpommernUnited statesStefan klotterCecilia hofvanderMartin welschofBioinvent internationalviewBioinvent international ab nasdaq stockholmBioinvent internationalBioinvent international abMerck co incMerck sharp dohmeMerck sharpNasdaq stockholmSenior director investorStabile ertrChart profi stefan klotter

BioInvent International: BioInvent Obtains IND Approval for Clinical Trial with anti-TNFR2 Antibody BI-1910

LUND, SWEDEN / ACCESSWIRE / June 2, 2023 / BioInvent International (STO:BINV)A differentiated -agonist- approach from BI-1808, the first-in-class antibody currently in phase 1 clinical developmentPhase

Martin welschofCecilia hofvanderBioinvent internationalviewBioinvent international ab nasdaq stockholmBioinvent internationalNasdaq stockholmInvestigational new drugSenior director investor

BioInvent receives Investigational New Drug approval for monoclonal antibody BI-1910

BI-1910 is now the second of the company s anti-tumour necrosis factor receptor 2 programmes to enter clinical development - News - PharmaTimes

Martin welschofInvestigational new drugInvestigational new drugMonoclonal antibodyI 1910

BioInvent and Transgene and report positive BT-001 data

Tumour treatment among all phase 1a cohorts in were concluded with no safety concerns - News - PharmaTimes

Martin welschofBioinvent internationalT 001

Resolutions at BioInvent s Annual General Meeting 2023

Lund, Sweden – April 27, 2023 – The Annual General Meeting of BioInvent International AB resolved to elect Erik Esveld as new Board member, to re-elect the Board members Natalie Berner,. | April 27, 2023

Thomas hechtVincent ossipowCecilia hofvanderLeonard kruimerBernd seizingerErik esveldNatalie bernerKristoffer bissessarRemuneration committeeAudit committeeBioinvent internationalBioinvent international ab nasdaq stockholmRd committeeSwedish companiesAnnual general meetingNasdaq stockholm

vimarsana © 2020. All Rights Reserved.